---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-211305"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2025-09-22T23:59:59+00:00"
generated_at: "2026-05-17T05:59:44.668263+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioAtla granted Nasdaq continued listing with conditions through Feb 2026

## Summary
- Nasdaq Panel approved continued listing pending transfer to Capital Market by Sept 26, 2025 (filed Sept 18).
- Must demonstrate compliance with Minimum Stockholders' Equity Requirement by Dec 31, 2025.
- Must demonstrate compliance with Minimum Bid Price Requirement by Feb 2, 2026.
- Company believes it can meet both deadlines but provides no assurance.
- Previously disclosed delisting risk from failure to meet bid price and equity requirements.

## SEC filing metadata
- accession: 0001193125-25-211305
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2025-09-22T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000119312525211305/0001193125-25-211305-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000119312525211305/bcab-20250916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-211305
- JSON: https://secwatch.observer/filing/0001193125-25-211305.json
- Plain text: https://secwatch.observer/filing/0001193125-25-211305.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.